- Target disease: Filarial diseases
- Main partners (since project start): Abbvie, USA; AWOL, UK; Liverpool School of Hygiene & Tropical Medicine, UK; University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology, Germany.
- Start date: March 2015
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; USAID, USA.
ABBV-4083 is a derivative of tylosin, a veterinary antibiotic which targets the worm-symbiont Wolbachia. DNDi is working in partnership with AbbVie and AWOL to develop the compound for filarial diseases, it is currently in full pre-clinical development. ABBV-4083 is orally available, induces a robust anti-Wolbachia effect in several in vivo models, demonstrates clear superiority over doxycycline, and is effective after a shorter dosing regimen.
Toxicology studies were completed in 2017, and an oral formulation was developed. In December, AbbVie began the first human trial of ABBV-4083 to test the drug’s safety in healthy volunteers and assist in the selection of doses for future trials. This Phase I study, conducted at at AbbVie’s Clinical Pharmacology Research Unit in Chicago, US is expected to be completed in 2018.
Preliminary safety and toxicology profiling of this compound suggests a favourable safety profile. Upon completion of toxicology studies and the development of an oral formulation, a Phase l study will be conducted in 2017. The aim will be to assess the safety, tolerability, and pharmacokinetics of ABBV-4083.
Last update: August 2018